Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC Implications for surgical and clinical outcomes

被引:16
|
作者
Cunnea, Paula [1 ]
Curry, Edward W. [1 ]
Christie, Elizabeth L. [2 ,3 ]
Nixon, Katherine [1 ]
Kwok, Chun Hei [1 ]
Pandey, Ahwan [2 ]
Wulandari, Ratri [1 ]
Thol, Kerstin [1 ]
Ploski, Jennifer [1 ]
Morera-Albert, Cristina [1 ]
McQuaid, Stephen [4 ]
Lozano-Kuehne, Jingky [5 ]
Clark, James J. [1 ]
Krell, Jonathan [1 ]
Stronach, Euan A. [1 ]
McNeish, Iain A. [1 ]
Bowtell, David D. L. [2 ,3 ]
Fotopoulou, Christina [1 ,6 ]
机构
[1] Imperial Coll London, Dept Surg & Canc, Div Canc, London W12 0NN, England
[2] Peter Maallum Canc Ctr, Melbourne, Vic 3000, Australia
[3] Univ Melbourne, Sir Peter Maallum Dept Oncol, Melbourne, Vic 3010, Australia
[4] Queens Univ Belfast, Belfast BT7 1NN, North Ireland
[5] Imperial Coll London, Expt Canc Med Ctr, Dept Surg & Canc, London W12 0NN, England
[6] Imperial Coll NHS Trust, West London Gynaecol Canc Ctr, London W12 0HS, England
基金
澳大利亚国家健康与医学研究理事会;
关键词
ADVANCED OVARIAN-CANCER; HOMOLOGOUS RECOMBINATION DEFICIENCY; GRADE SEROUS CARCINOMA; COPY NUMBER; QUALITY INDICATORS; EUROPEAN-SOCIETY; EXPRESSION; RECOMMENDATIONS; AMPLIFICATION; SURGERY;
D O I
10.1016/j.xcrm.2023.101055
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor simpler sympodial evolution. Three distinct tumor evolutionary patterns from primary to relapse are identified, demonstrating recurrent disease may emerge from pre-existing or newly detected clones. Crucially, we identify spatial heterogeneity for clinically actionable homologous recombination deficiency scores and for poor prognosis biomarkers CCNE1 and MYC. Copy-number signature, phenotypic, proteomic, and proliferative-index heterogeneity further highlight HGSOC complexity. This study explores HGSOC evolution and dissemination across space and time, its impact on optimal surgical cytoreductive effort and clinical outcomes, and its consequences for clinical decision-making.
引用
收藏
页数:21
相关论文
共 50 条
  • [11] Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma
    Danilenko, Marina
    Clifford, Steven C.
    Schwalbe, Edward C.
    PHARMACOLOGY & THERAPEUTICS, 2021, 228
  • [12] Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer
    Mony, Jyothi Thyagabhavan
    Schuchert, Matthew J.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [13] Clinical Implications of Intra-Tumoral Variation in HER2 Expression in Breast Cancer
    Bonham, M.
    Lal, A.
    Devries, S.
    Hwang, E.
    Rabban, J.
    Waldman, F.
    Chen, Y.
    LABORATORY INVESTIGATION, 2009, 89 : 31A - 31A
  • [14] The intra-tumoral heterogeneity in glioblastoma — a limitation for prognostic value of epigenetic markers?
    Sippl Christoph
    Saenz Alicia
    Teping Fritz
    Trenkpohl Vanessa
    Ketter Ralf
    Kim Yoo Jin
    Linsler Stefan
    Oertel Joachim
    Acta Neurochirurgica, 2023, 165 : 1635 - 1644
  • [15] Clinical Implications of Intra-Tumoral Variation in HER2 Expression in Breast Cancer
    Bonham, M.
    Lal, A.
    Devries, S.
    Hwang, E.
    Rabban, J.
    Waldman, F.
    Chen, Y.
    MODERN PATHOLOGY, 2009, 22 : 31A - 31A
  • [16] The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis
    Roberts, Cai M.
    Cardenas, Carlos
    Tedja, Roslyn
    CANCERS, 2019, 11 (08)
  • [17] Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer
    Oshi, Masanori
    Kawaguchi, Tsutomu
    Yan, Li
    Peng, Xuan
    Qi, Qianya
    Tian, Wanqing
    Schulze, Amy
    Mcdonald, Kerry-Ann
    Narayanan, Sumana
    Young, Jessica
    Liu, Song
    Morris, Luc G. T.
    Chan, Timothy A.
    Kalinski, Pawel
    Matsuyama, Ryusei
    Otsuji, Eigo
    Endo, Itaru
    Takabe, Kazuaki
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (07): : 3628 - +
  • [18] THE INTRA-TUMORAL SPATIAL HETEROGENEITY OF T CELL ANTIGENS IN GLIOBLASTOMA: AN INTEGRATED MULTI-OMICS APPROACH
    Medici, Gioele
    Wacker, Marcel
    Dubbelaar, Marissa
    Schwitalla, Carolin
    Hanssen, Friederike
    Schulz, Daniel
    Vasella, Flavio
    Rushing, Elisabeth
    Bauer, Jens
    Bodenmiller, Bernd
    Rammensee, Hans-Georg
    Regli, Luca
    Walz, Juliane
    Weller, Michael
    Neidert, Marian
    NEURO-ONCOLOGY, 2022, 24 : 137 - 137
  • [19] INTRA-TUMORAL HETEROGENEITY OF DNA METHYLATION PROFILING AND CELLULAR COMPOSITION IN GLIOBLASTOMA
    Matsumoto, Yuji
    Singh, Omkar
    Garcia, Jose
    Kwak, Sunwoo
    Abdullaev, Zied
    Freeburg, Nelson
    Silverbush, Dana
    Aldape, Kenneth
    Davatzikos, Christos
    Nasrallah, Maclean
    NEURO-ONCOLOGY, 2024, 26
  • [20] The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?
    Christoph, Sippl
    Alicia, Saenz
    Fritz, Teping
    Vanessa, Trenkpohl
    Ralf, Ketter
    Jin, Kim Yoo
    Stefan, Linsler
    Joachim, Oertel
    ACTA NEUROCHIRURGICA, 2023, 165 (06) : 1635 - 1644